These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 15930354

  • 1. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805.
    Byrd JC, Peterson BL, Gabrilove J, Odenike OM, Grever MR, Rai K, Larson RA, Cancer and Leukemia Group B.
    Clin Cancer Res; 2005 Jun 01; 11(11):4176-81. PubMed ID: 15930354
    [Abstract] [Full Text] [Related]

  • 2. Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity.
    Flinn IW, Byrd JC, Bartlett N, Kipps T, Gribben J, Thomas D, Larson RA, Rai K, Petric R, Ramon-Suerez J, Gabrilove J, Grever MR.
    Leuk Res; 2005 Nov 01; 29(11):1253-7. PubMed ID: 15916806
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.
    Van Veldhuizen PJ, Faulkner JR, Lara PN, Gumerlock PH, Goodwin JW, Dakhil SR, Gross HM, Flanigan RC, Crawford ED, Southwest Oncology Group.
    Cancer Chemother Pharmacol; 2005 Jul 01; 56(1):39-45. PubMed ID: 15791454
    [Abstract] [Full Text] [Related]

  • 4. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C.
    Leukemia; 2003 Feb 01; 17(2):323-7. PubMed ID: 12592330
    [Abstract] [Full Text] [Related]

  • 5. Flavopiridol in chronic lymphocytic leukemia: a concise review.
    Christian BA, Grever MR, Byrd JC, Lin TS.
    Clin Lymphoma Myeloma; 2009 Feb 01; 9 Suppl 3():S179-85. PubMed ID: 19778838
    [Abstract] [Full Text] [Related]

  • 6. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network.
    Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA, Minnie Pearl Cancer Research Network.
    J Clin Oncol; 2003 May 01; 21(9):1746-51. PubMed ID: 12721250
    [Abstract] [Full Text] [Related]

  • 7. A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study.
    Grendys EC, Blessing JA, Burger R, Hoffman J.
    Gynecol Oncol; 2005 Aug 01; 98(2):249-53. PubMed ID: 15978659
    [Abstract] [Full Text] [Related]

  • 8. A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
    Shapiro GI, Supko JG, Patterson A, Lynch C, Lucca J, Zacarola PF, Muzikansky A, Wright JJ, Lynch TJ, Rollins BJ.
    Clin Cancer Res; 2001 Jun 01; 7(6):1590-9. PubMed ID: 11410495
    [Abstract] [Full Text] [Related]

  • 9. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C, Morabito F, Kropp MG, Callea V, Iuliano F, Oriana V, Levato D, Nobile F, Molica S, Brugiatelli M.
    Haematologica; 1999 Apr 01; 84(4):317-23. PubMed ID: 10190945
    [Abstract] [Full Text] [Related]

  • 10. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S, Moore JO, Boyd TE, Larratt LM, Skotnicki A, Koziner B, Chanan-Khan AA, Seymour JF, Bociek RG, Pavletic S, Rai KR.
    J Clin Oncol; 2007 Mar 20; 25(9):1114-20. PubMed ID: 17296974
    [Abstract] [Full Text] [Related]

  • 11. Flavopiridol in the treatment of chronic lymphocytic leukemia.
    Christian BA, Grever MR, Byrd JC, Lin TS.
    Curr Opin Oncol; 2007 Nov 20; 19(6):573-8. PubMed ID: 17906454
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group.
    Bergmann MA, Goebeler ME, Herold M, Emmerich B, Wilhelm M, Ruelfs C, Boening L, Hallek MJ, German CLL Study Group.
    Haematologica; 2005 Oct 20; 90(10):1357-64. PubMed ID: 16219572
    [Abstract] [Full Text] [Related]

  • 13. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
    Knauf WU, Lissichkov T, Aldaoud A, Liberati A, Loscertales J, Herbrecht R, Juliusson G, Postner G, Gercheva L, Goranov S, Becker M, Fricke HJ, Huguet F, Del Giudice I, Klein P, Tremmel L, Merkle K, Montillo M.
    J Clin Oncol; 2009 Sep 10; 27(26):4378-84. PubMed ID: 19652068
    [Abstract] [Full Text] [Related]

  • 14. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
    Valentini V, Morganti AG, Gambacorta MA, Mohiuddin M, Doglietto GB, Coco C, De Paoli A, Rossi C, Di Russo A, Valvo F, Bolzicco G, Dalla Palma M, Study Group for Therapies of Rectal Malignancies (STORM).
    Int J Radiat Oncol Biol Phys; 2006 Mar 15; 64(4):1129-39. PubMed ID: 16414206
    [Abstract] [Full Text] [Related]

  • 15. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia.
    Montillo M, Tedeschi A, O'Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating MJ.
    Cancer; 2003 Jan 01; 97(1):114-20. PubMed ID: 12491512
    [Abstract] [Full Text] [Related]

  • 16. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, Böttcher S, Staib P, Kiehl M, Eckart MJ, Kranz G, Goede V, Elter T, Bühler A, Winkler D, Kneba M, Döhner H, Eichhorst BF, Hallek M, Wendtner CM.
    J Clin Oncol; 2011 Sep 10; 29(26):3559-66. PubMed ID: 21844497
    [Abstract] [Full Text] [Related]

  • 17. Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children's Oncology Group Study.
    Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G, Children's Oncology Group Study.
    J Clin Oncol; 2005 Dec 20; 23(36):9179-86. PubMed ID: 16361620
    [Abstract] [Full Text] [Related]

  • 18. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ.
    J Clin Oncol; 2008 Jan 10; 26(2):196-203. PubMed ID: 18182662
    [Abstract] [Full Text] [Related]

  • 19. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
    Martell RE, Peterson BL, Cohen HJ, Petros WP, Rai KR, Morrison VA, Elias L, Shepherd L, Hines J, Larson RA, Schiffer CA, Hurwitz HI.
    Cancer Chemother Pharmacol; 2002 Jul 10; 50(1):37-45. PubMed ID: 12111110
    [Abstract] [Full Text] [Related]

  • 20. Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia.
    Robak T, Smolewski P, Cebula B, Grzybowska-Izydorczyk O, Błoński JZ.
    Eur J Haematol; 2007 Aug 10; 79(2):107-13. PubMed ID: 17635235
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.